The Doyle and Hammond Labs created hydrogel particles for biologics. In a study appearing in Advanced Healthcare Materials, researchers delivered the cancer immunotherapy pembrolizumab (Keytruda) via single injection. Normally, the drug must be administered in dilute solution over several hours, in a hospital or clinic.
Eyeing FDA approval in the next few years, the team notes their platform could also resuscitate drugs for which adequately concentrated formulations have remained elusive. This innovative approach can improve the patient experience, decrease the healthcare costs, and improve access to healthcare while bringing value to the industry.